“Physican-Directed Applications”: A Clinician’s Case To Open Up Off-Label Promotion
This article was originally published in RPM Report
Executive Summary
In testimony during the House Energy & Commerce Committee’s “21st Century Cures” initiative, a rheumatologist makes the case for broader access to off-label use information – but not for eliminating FDA review before dissemination.